These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

275 related items for PubMed ID: 37231847

  • 61. Novel Score to Predict Immunoglobulin Resistance in Kawasaki Disease.
    Natarajan RK, Bhoopalan SV, Cross C, Shah R, Rothman A.
    Pediatr Cardiol; 2023 Oct; 44(7):1546-1551. PubMed ID: 37173579
    [Abstract] [Full Text] [Related]

  • 62. Risk stratification in the decision to include prednisolone with intravenous immunoglobulin in primary therapy of Kawasaki disease.
    Kobayashi T, Inoue Y, Otani T, Morikawa A, Kobayashi T, Takeuchi K, Saji T, Sonobe T, Ogawa S, Miura M, Arakawa H.
    Pediatr Infect Dis J; 2009 Jun; 28(6):498-502. PubMed ID: 19504733
    [Abstract] [Full Text] [Related]

  • 63. Verification of risk scores to predict i.v. immunoglobulin resistance in incomplete Kawasaki disease.
    Kanamitsu K, Kakimoto H, Shimada A, Nakata Y, Ochi H, Watanabe H, Iwasaki Y, Tokorodani C, Kanazawa A, Maruyama H, Miyazawa M, Nishiuchi R, Kikkawa K.
    Pediatr Int; 2016 Feb; 58(2):146-51. PubMed ID: 26190225
    [Abstract] [Full Text] [Related]

  • 64. Relationship between post-IVIG IgG levels and clinical outcomes in Kawasaki disease patients: new insight into the mechanism of action of IVIG.
    Goto R, Inuzuka R, Shindo T, Namai Y, Oda Y, Harita Y, Oka A.
    Clin Rheumatol; 2020 Dec; 39(12):3747-3755. PubMed ID: 32458247
    [Abstract] [Full Text] [Related]

  • 65. A low-frequency IL4R locus variant in Japanese patients with intravenous immunoglobulin therapy-unresponsive Kawasaki disease.
    Amano Y, Akazawa Y, Yasuda J, Yoshino K, Kojima K, Kobayashi N, Matsuzaki S, Nagasaki M, Kawai Y, Minegishi N, Ishida N, Motoki N, Hachiya A, Nakazawa Y, Yamamoto M, Koike K, Takeshita T.
    Pediatr Rheumatol Online J; 2019 Jul 03; 17(1):34. PubMed ID: 31269967
    [Abstract] [Full Text] [Related]

  • 66. Clinical characteristics of Kawasaki disease in Polish children: A retrospective study.
    Smorczewska-Kiljan A, Marszał M, Friedman-Gruszczyńska J, Wieteska-Klimczak A, Książyk J, Jaworski M, Buda P.
    Kardiol Pol; 2022 Jul 03; 80(6):657-663. PubMed ID: 35380006
    [Abstract] [Full Text] [Related]

  • 67. Aspirin Dose in Kawasaki Disease: The Ongoing Battle.
    Dhanrajani A, Chan M, Pau S, Ellsworth J, Petty R, Guzman J.
    Arthritis Care Res (Hoboken); 2018 Oct 03; 70(10):1536-1540. PubMed ID: 29287309
    [Abstract] [Full Text] [Related]

  • 68. Efficacy and safety of intravenous immunoglobulin plus prednisolone therapy in patients with Kawasaki disease (Post RAISE): a multicentre, prospective cohort study.
    Miyata K, Kaneko T, Morikawa Y, Sakakibara H, Matsushima T, Misawa M, Takahashi T, Nakazawa M, Tamame T, Tsuchihashi T, Yamashita Y, Obonai T, Chiga M, Hori N, Komiyama O, Yamagishi H, Miura M, Post RAISE group.
    Lancet Child Adolesc Health; 2018 Dec 03; 2(12):855-862. PubMed ID: 30337183
    [Abstract] [Full Text] [Related]

  • 69. Risk Model Development and Validation for Prediction of Coronary Artery Aneurysms in Kawasaki Disease in a North American Population.
    Son MBF, Gauvreau K, Tremoulet AH, Lo M, Baker AL, de Ferranti S, Dedeoglu F, Sundel RP, Friedman KG, Burns JC, Newburger JW.
    J Am Heart Assoc; 2019 Jun 04; 8(11):e011319. PubMed ID: 31130036
    [Abstract] [Full Text] [Related]

  • 70. Responsiveness to intravenous immunoglobulins and occurrence of coronary artery abnormalities in a single-center cohort of Italian patients with Kawasaki syndrome.
    Rigante D, Valentini P, Rizzo D, Leo A, De Rosa G, Onesimo R, De Nisco A, Angelone DF, Compagnone A, Delogu AB.
    Rheumatol Int; 2010 Apr 04; 30(6):841-6. PubMed ID: 20049445
    [Abstract] [Full Text] [Related]

  • 71. Timing of intravenous immunoglobulin treatment and risk of coronary artery abnormalities in children with Kawasaki disease.
    Bal AK, Prasad D, Umali Pamintuan MA, Mammen-Prasad E, Petrova A.
    Pediatr Neonatol; 2014 Oct 04; 55(5):387-92. PubMed ID: 24636168
    [Abstract] [Full Text] [Related]

  • 72. [Association between duration of fever before treatment and intravenous immunoglobulin resistance in Kawasaki disease].
    Wang X, Pan SL, DU ZH, Ji ZX, Luo G, Sun HX, Ma SJ.
    Zhongguo Dang Dai Er Ke Za Zhi; 2022 Apr 15; 24(4):399-404. PubMed ID: 35527415
    [Abstract] [Full Text] [Related]

  • 73. P2RY12:rs7637803 TT variant genotype increases coronary artery aneurysm risk in Kawasaki disease in a southern Chinese population.
    Lu Z, Xu Y, Fu L, Tan Y, Che D, Huang P, Pi L, Zhou H, Liang X, Zhang L, Gu X.
    J Gene Med; 2019 Jan 15; 21(1):e3066. PubMed ID: 30576025
    [Abstract] [Full Text] [Related]

  • 74. Predictive Value of Serum Lipid for Intravenous Immunoglobulin Resistance and Coronary Artery Lesion in Kawasaki Disease.
    Shao S, Zhou K, Liu X, Liu L, Wu M, Deng Y, Duan H, Li Y, Hua Y, Wang C.
    J Clin Endocrinol Metab; 2021 Sep 27; 106(10):e4210-e4220. PubMed ID: 33837779
    [Abstract] [Full Text] [Related]

  • 75. Predicting Coronary Artery Aneurysms in Kawasaki Disease at a North American Center: An Assessment of Baseline z Scores.
    Son MBF, Gauvreau K, Kim S, Tang A, Dedeoglu F, Fulton DR, Lo MS, Baker AL, Sundel RP, Newburger JW.
    J Am Heart Assoc; 2017 May 31; 6(6):. PubMed ID: 28566299
    [Abstract] [Full Text] [Related]

  • 76. The changes of coagulation profiles in Kawasaki disease and its associations with clinical classification, intravenous immunoglobulin responsiveness and coronary artery involvement.
    Li DT, Yang Q, Xia CY, Zhang YF, Cai Y, Wu SQ, Jiang Q, Hu P.
    Clin Exp Med; 2024 Aug 06; 24(1):177. PubMed ID: 39105936
    [Abstract] [Full Text] [Related]

  • 77. Japanese scoring systems to predict resistance to intravenous immunoglobulin in Kawasaki disease were unreliable for Caucasian Israeli children.
    Arane K, Mendelsohn K, Mimouni M, Mimouni F, Koren Y, Brik Simon D, Bahat H, Hanna Helou M, Mendelson A, Hezkelo N, Glatstein M, Berkun Y, Eisenstein E, Butbul YA, Brik R, Hashkes PJ, Uziel Y, Harel L, Amarilyo G.
    Acta Paediatr; 2018 Dec 06; 107(12):2179-2184. PubMed ID: 29797463
    [Abstract] [Full Text] [Related]

  • 78. The time option of IVIG treatment is associated with therapeutic responsiveness and coronary artery abnormalities but not with clinical classification in the acute episode of Kawasaki disease.
    Samadli S, Liu FF, Mammadov G, Wang JJ, Liu HH, Wu YF, Luo HH, Wu Y, Chen WX, Zhang DD, Wei W, Hu P.
    Pediatr Rheumatol Online J; 2019 Jul 31; 17(1):53. PubMed ID: 31366406
    [Abstract] [Full Text] [Related]

  • 79. Infliximab Plus Intravenous Immunoglobulin (IVIG) Versus IVIG Alone as Initial Therapy in Children With Kawasaki Disease Presenting With Coronary Artery Lesions: Is Dual Therapy More Effective?
    Jone PN, Anderson MS, Mulvahill MJ, Heizer H, Glodé MP, Dominguez SR.
    Pediatr Infect Dis J; 2018 Oct 31; 37(10):976-980. PubMed ID: 29461447
    [Abstract] [Full Text] [Related]

  • 80. Failure to Predict High-risk Kawasaki Disease Patients in a Population-based Study Cohort in Germany.
    Jakob A, von Kries R, Horstmann J, Hufnagel M, Stiller B, Berner R, Schachinger E, Meyer K, Obermeier V.
    Pediatr Infect Dis J; 2018 Sep 31; 37(9):850-855. PubMed ID: 29406464
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 14.